ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/LAG3
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/LAG3
32
trial(s) found.
NCT06561386
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1% (
RELATIVITY1093
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06288191
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II to IV (M0) Resectable Cutaneous Squamous Cell Carcinoma (
MIA2023-490
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06190951
Curative
Phase 2 / Phase 3
Recruiting
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma (
R3767-ONC-2208
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06161441
Advanced
Phase 2
Recruiting
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC (
R3767-ONC-2266
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06151236
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell Carcinoma (
MIA2023-489
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Merkel cell carcinoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06112314
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (
PRISM-MEL-301
anti-PD-1 monoclonal antibody
bispecific T-cell engager,PRAME-targeting
+ anti-LAG3 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05908786
Curative
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC) (
GO44457
)
Atezolizumab
Bevacizumab
Tiragolumab
Tobemstomig
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ bispecific PD-1/LAG3 antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05800015
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels (
R3767-ONC-2236
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05785767
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% (
R3767-ONC-2235
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
2650 - Wagga Wagga - Riverina Cancer Care Centre
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT05608291
Curative
Phase 3
Recruiting
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma (
R3767-ONC-2055
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT05418972
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (
Neo-ReNi-II
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT05352672
Advanced
Phase 3
Recruiting
A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (
R3767-ONC-2011
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4215 - Southport - Gold Coast University Hospital (SUSPENDED)
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT04938817
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) (
3475-B98
)
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital (COMPLETED)
WA
6009 - Nedlands - Hollywood Private Hospital
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ bispecific PD-1/LAG3 antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04305054
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (
3475-02B
)
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology (COMPLETED)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (SUSPENDED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06036836
Advanced
Phase 2
Active not recruiting
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010) (
4280A-010
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Endometrial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05909904
Advanced
Phase 2
Active not recruiting
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
BGB-HNSCC-201
)
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Gold Coast Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05852691
Advanced
Phase 2
Active not recruiting
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (
CO44194
)
anti-PD-1 monoclonal antibody
bispecific PD-1/LAG3 antibody
taxane
Breast cancer
VIC
3021 - St Albans - Western Health - Sunshine Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05845814
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B (
3475-04B
)
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Urothelial carcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
+ bispecific PD-1/LAG3 antibody
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05775289
Advanced
Phase 2
Active not recruiting
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
BO44178
)
anti-PD-1 monoclonal antibody
bispecific PD-1/LAG3 antibody
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05645692
Advanced
Phase 2
Not recruiting
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy (
BO44157
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05635708
Advanced
Phase 2
Active not recruiting
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (
BGB-LC-201
)
anti-PD-1 monoclonal antibody
+ anti-LAG3 monoclonal antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2086 - Frenchs Forest - Northern Beaches Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - One Clinical Research
NCT05625399
Advanced
Phase 3
Not recruiting
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma (
RELATIVITY-127
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2650 - Wagga Wagga - Riverina Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3844 - Traralgon - Latrobe Regional Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05609370
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (
BGB-A317-LBL-007-201
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2650 - Wagga Wagga - Riverina Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT05572463
Advanced
Phase 1 / Phase 2
Withdrawn
A Randomized, Open-label, Multicenter, Multi-arm, Phase 1b/2 Platform Study to Evaluate Safety and Efficacy of Investigational Immunotherapies in Participants With Previously Treated Unresectable or Metastatic Melanoma (
PLATFORM201
)
IBI110
Sintilimab
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
+ anti-LAG3 monoclonal antibody
Cutaneous melanoma
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05419388
Advanced
Phase 1 / Phase 2
Not recruiting
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (
BP43963
)
bispecific PD-1/LAG3 antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05337137
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (
RELATIVITY-106
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
placebo
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05328908
Advanced
Phase 3
Active not recruiting
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer (
RELATIVITY-123
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Tipiracil Hydrochloride
Trifluridine
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
Colorectal adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2650 - Wagga Wagga - Riverina Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05116202
Advanced
Phase 1 / Phase 2
*paused
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (
BO43328
)
Atezolizumab
Ipilimumab
Nivolumab
RO7247669
Tiragolumab
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
+ bispecific PD-1/LAG3 antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (16)
Active not recruiting (9)
Not recruiting (3)
Enrolling by invitation (1)
paused (1)
Withdrawn (1)
*paused (1)
Recruitment Country and State
NSW (24)
VIC (20)
WA (17)
QLD (16)
SA (11)
NZ (6)
TAS (1)
Phase
Phase 1 / Phase 2 (10)
Phase 2 (11)
Phase 2 / Phase 3 (3)
Phase 3 (8)
Trial Type
Advanced (26)
Curative (6)
Cancer Therapy Class
LAG3
100%
PD-1
100%
PD-1/PD-L1
100%
VEGF
28%
TIGIT
25%
PD-L1
13%
CTLA4
13%
KIT
9%
PDGFR
9%
VEGFR
9%
HPK1
6%
OX40
6%
PARP
6%
RET
6%
PRAME
3%
ILT4
3%
HIF2a
3%
IL-6
3%
PPAR-alpha
3%
ERBB2
3%
VEGFR1
3%
VEGFR2
3%
VEGFR3
3%
TIM3
3%
NECTIN4
3%
FGFR
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR3
3%
FGFR4
3%
Facility
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (11)
6150 - Murdoch - Fiona Stanley Hospital (9)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
3168 - Clayton - Monash Medical Centre (6)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (5)
3004 - Melbourne, Southbank - Alfred Health (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
5112 - Elizabeth Vale - Lyell McEwin Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
2109 - North Ryde - Macquarie University Hospital (4)
2650 - Wagga Wagga - Riverina Cancer Care Centre (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (4)
6009 - Nedlands - One Clinical Research (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
6009 - Nedlands - Linear Clinical Research (3)
4032 - Chermside - The Prince Charles Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
5042 - Bedford Park - Flinders Medical Centre (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
4215 - Southport - Tasman Oncology (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2060 - North Sydney - Mater Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4215 - Southport - Gold Coast Private Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Solid tumour
Melanoma
Lung cancer
Respiratory tract cancer
Thoracic cancer
Non-small cell lung cancer
Gastrointestinal cancer
Skin cancer
Non-melanoma skin cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Upper gastrointestinal cancer
Urogenital cancer
Cutaneous squamous cell carcinoma
Urothelial carcinoma
Colorectal cancer
Lower gastrointestinal cancer
Merkel cell carcinoma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Haematological malignancy
Endometrial cancer
Endometrial carcinoma
Gynaecological cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Breast cancer
Clear cell renal cell carcinoma
Kidney cancer
Cutaneous melanoma
Colorectal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy